Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

✍ Scribed by Willemze, R.; Suciu, S.; Muus, P.; Halkes, C. J. M.; Meloni, G.; Meert, L.; Karrasch, M.; Rapion, J.; Vignetti, M.; Amadori, S.; de Witte, T.; Marie, J. P.

• Book ID: 125344159
• Publisher: Springer
• Year: 2014
• Tongue: English
• Weight: 197 KB
• Volume: 93
• Category: Article
• ISSN: 0939-5555
• DOI: 10.1007/s00277-014-2056-6